Cargando…

Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study

BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Belay, Wubishet, Dessie, Azene, Ahmed, Hayat, Gedlu, Etsegenet, Mariyo, Abinet, Shehibo, Abdulkadir, Tigabu, Zemene, Aliyu, Muktar H., Soslow, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809239/
https://www.ncbi.nlm.nih.gov/pubmed/35109807
http://dx.doi.org/10.1186/s12872-022-02473-4
_version_ 1784643983888089088
author Belay, Wubishet
Dessie, Azene
Ahmed, Hayat
Gedlu, Etsegenet
Mariyo, Abinet
Shehibo, Abdulkadir
Tigabu, Zemene
Aliyu, Muktar H.
Soslow, Jonathan
author_facet Belay, Wubishet
Dessie, Azene
Ahmed, Hayat
Gedlu, Etsegenet
Mariyo, Abinet
Shehibo, Abdulkadir
Tigabu, Zemene
Aliyu, Muktar H.
Soslow, Jonathan
author_sort Belay, Wubishet
collection PubMed
description BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospective study was performed on children aged 5–17 years with RHD in Ethiopia. Good adherence was defined as at least 80% completion of benzathine penicillin (BPG) or oral Amoxicillin within the previous year. The primary outcome measure was adherence to prophylaxis, expressed as a proportion. Socio-demographics, severity of RHD, and ARF recurrence were evaluated. RESULTS: A total of 337 children with a mean age of 12.9 ± 2.6 years were included. The majority (73%) had severe aortic/mitral disease. Participants were on BPG (80%) or Amoxicillin (20%) prophylaxis. Female sex (P = 0.04) use of BPG (0.03) and shorter mean duration of prophylaxis in months (48.5 ± 31.5 vs. 60.7 ± 33, respectively, P < 0.008) predicted good adherence. Running out of medications (35%), interrupted follow-up (27%), and the COVID-19 pandemic (26%) were the most common reasons for missing prophylaxis. Recurrence of ARF was higher in participants on Amoxicillin compared with BPG (40% vs. 16%, P < 0.001) and in those with poor adherence compared with good adherence (36.8% vs. 17.9%, respectively, P = 0.005). Type and duration of prophylaxis (OR 0.5, CI = 0.24, 0.9, P = 0.02; OR = 1.1, CI = 1.1, 1.2, P = 0.04, respectively), and sex (OR = 1.9, CI = 1.1, 3.4, P = 0.03) were independent predictors of poor adherence. CONCLUSION: Poor adherence is prevalent in Ethiopian children living with RHD. Amoxicillin is a suboptimal option for prophylaxis as its use is associated with lower adherence and a higher rate of ARF recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02473-4.
format Online
Article
Text
id pubmed-8809239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88092392022-02-02 Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study Belay, Wubishet Dessie, Azene Ahmed, Hayat Gedlu, Etsegenet Mariyo, Abinet Shehibo, Abdulkadir Tigabu, Zemene Aliyu, Muktar H. Soslow, Jonathan BMC Cardiovasc Disord Research BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospective study was performed on children aged 5–17 years with RHD in Ethiopia. Good adherence was defined as at least 80% completion of benzathine penicillin (BPG) or oral Amoxicillin within the previous year. The primary outcome measure was adherence to prophylaxis, expressed as a proportion. Socio-demographics, severity of RHD, and ARF recurrence were evaluated. RESULTS: A total of 337 children with a mean age of 12.9 ± 2.6 years were included. The majority (73%) had severe aortic/mitral disease. Participants were on BPG (80%) or Amoxicillin (20%) prophylaxis. Female sex (P = 0.04) use of BPG (0.03) and shorter mean duration of prophylaxis in months (48.5 ± 31.5 vs. 60.7 ± 33, respectively, P < 0.008) predicted good adherence. Running out of medications (35%), interrupted follow-up (27%), and the COVID-19 pandemic (26%) were the most common reasons for missing prophylaxis. Recurrence of ARF was higher in participants on Amoxicillin compared with BPG (40% vs. 16%, P < 0.001) and in those with poor adherence compared with good adherence (36.8% vs. 17.9%, respectively, P = 0.005). Type and duration of prophylaxis (OR 0.5, CI = 0.24, 0.9, P = 0.02; OR = 1.1, CI = 1.1, 1.2, P = 0.04, respectively), and sex (OR = 1.9, CI = 1.1, 3.4, P = 0.03) were independent predictors of poor adherence. CONCLUSION: Poor adherence is prevalent in Ethiopian children living with RHD. Amoxicillin is a suboptimal option for prophylaxis as its use is associated with lower adherence and a higher rate of ARF recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02473-4. BioMed Central 2022-02-02 /pmc/articles/PMC8809239/ /pubmed/35109807 http://dx.doi.org/10.1186/s12872-022-02473-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Belay, Wubishet
Dessie, Azene
Ahmed, Hayat
Gedlu, Etsegenet
Mariyo, Abinet
Shehibo, Abdulkadir
Tigabu, Zemene
Aliyu, Muktar H.
Soslow, Jonathan
Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title_full Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title_fullStr Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title_full_unstemmed Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title_short Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
title_sort secondary prevention of rheumatic heart disease in ethiopia: a multicenter study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809239/
https://www.ncbi.nlm.nih.gov/pubmed/35109807
http://dx.doi.org/10.1186/s12872-022-02473-4
work_keys_str_mv AT belaywubishet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT dessieazene secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT ahmedhayat secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT gedluetsegenet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT mariyoabinet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT shehiboabdulkadir secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT tigabuzemene secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT aliyumuktarh secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy
AT soslowjonathan secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy